203 related articles for article (PubMed ID: 16138223)
1. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.
Rodrigues AC; Rebecchi IM; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
Braz J Med Biol Res; 2005 Sep; 38(9):1389-97. PubMed ID: 16138223
[TBL] [Abstract][Full Text] [Related]
2. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
[TBL] [Abstract][Full Text] [Related]
3. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
[TBL] [Abstract][Full Text] [Related]
4. Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations.
Taegtmeyer AB; Breen JB; Smith J; Rogers P; Kullak-Ublick GA; Yacoub MH; Banner NR; Barton PJ
J Cardiovasc Transl Res; 2011 Jun; 4(3):304-12. PubMed ID: 21445698
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.
Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
Am J Cardiol; 2004 Apr; 93(8):1046-50. PubMed ID: 15081455
[TBL] [Abstract][Full Text] [Related]
6. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.
Cascorbi I; Gerloff T; Johne A; Meisel C; Hoffmeyer S; Schwab M; Schaeffeler E; Eichelbaum M; Brinkmann U; Roots I
Clin Pharmacol Ther; 2001 Mar; 69(3):169-74. PubMed ID: 11240981
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
8. Frequency of common MDR1 gene variants in a Polish population.
Kurzawski M; Pawlik A; Górnik W; Droździk M
Pharmacol Rep; 2006; 58(1):35-40. PubMed ID: 16531628
[TBL] [Abstract][Full Text] [Related]
9. The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Biol Rep; 2014 Jan; 41(1):331-6. PubMed ID: 24213830
[TBL] [Abstract][Full Text] [Related]
10. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
[TBL] [Abstract][Full Text] [Related]
11. Frequency of G2677T/A and C3435T polymorphisms of MDR1 gene in preeclamptic women.
Bogacz A; Mrozikiewicz PM; Deka-Pawlik D; Seremak-Mrozikiewicz A; Bartkowiak-Wieczorek J; Barlik M; Drews K; Kowalska A; Grześkowiak E
Ginekol Pol; 2013 Sep; 84(9):781-7. PubMed ID: 24191517
[TBL] [Abstract][Full Text] [Related]
12. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
13. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
15. Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
Lagos J; Zambrano T; Rosales A; Salazar LA
Mol Diagn Ther; 2014 Aug; 18(4):435-43. PubMed ID: 24615250
[TBL] [Abstract][Full Text] [Related]
16. Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR.
Chen B; Fang J; Zhang W; Jin Z; Yu Z; Cai W
J Clin Lab Anal; 2009; 23(2):110-6. PubMed ID: 19288456
[TBL] [Abstract][Full Text] [Related]
17. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
18. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
[TBL] [Abstract][Full Text] [Related]
19. Identification of functionally variant MDR1 alleles among European Americans and African Americans.
Kim RB; Leake BF; Choo EF; Dresser GK; Kubba SV; Schwarz UI; Taylor A; Xie HG; McKinsey J; Zhou S; Lan LB; Schuetz JD; Schuetz EG; Wilkinson GR
Clin Pharmacol Ther; 2001 Aug; 70(2):189-99. PubMed ID: 11503014
[TBL] [Abstract][Full Text] [Related]
20. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Willrich MA; Hirata MH; Genvigir FD; Arazi SS; Rebecchi IM; Rodrigues AC; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2008 Dec; 398(1-2):15-20. PubMed ID: 18727922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
